title: Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study.
abstract: Nifeviroc is a novel CCR5 antagonist used for the treatment of HIV type-1 infection. A LC-ESI-MS/MS method for the determination of nifeviroc in human plasma was developed and validated. The calibration curve (r(2)=0.9993) of nifeviroc was established at the range of 1.924-2935 μg L(-1). The intra- and inter-day precisions (RSD%) were all less than 7%, and the accuracies at three concentration levels were all within 100 ± 5%. This validated method was then successfully applied to a pharmacokinetic study in health Chinese volunteers.
authors.affiliation: School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wu
authors.forename: Dong
authors.initials: D
authors.lastname: Xie
authors.forename: Zeneng
authors.initials: Z
authors.lastname: Cheng
authors.forename: Zhi
authors.initials: Z
authors.lastname: Liu
authors.forename: Liling
authors.initials: L
authors.lastname: Ran
authors.forename: Zhenkun
authors.initials: Z
authors.lastname: Gu
authors.forename: Peng
authors.initials: P
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D065100:CCR5 Receptor Antagonists; D002138:Calibration; D002219:Carbamates / Q000097:blood* / Q000493:pharmacokinetics*; D002853:Chromatography, Liquid / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D011759:Pyrrolidines / Q000097:blood* / Q000493:pharmacokinetics*; D012015:Reference Standards; D015203:Reproducibility of Results; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*; D055815:Young Adult
chemical_list: D065100:CCR5 Receptor Antagonists; D002219:Carbamates; D010919:Placebos; D011759:Pyrrolidines; C570101:nifeviroc